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Effect of local anaesthetic infiltration on chronic
postsurgical pain after total hip and knee
replacement: the APEX randomised
controlled trials
Vikki Wyldea,*, Erik Lenguerranda, Rachael Gooberman-Hilla, Andrew D. Beswicka, Elsa Marquesb, Sian Nobleb,
Jeremy Horwoodb, Mark Pykec, Paul Diepped, Ashley W. Bloma
Abstract
Total hip replacement (THR) and total knee replacement (TKR) are usually effective at relieving pain; however, 7% to 23% of patients
experience chronic postsurgical pain. These trials aimed to investigate the effect of local anaesthetic wound infiltration on pain
severity at 12 months after primary THR or TKR for osteoarthritis. Between November 2009 and February 2012, 322 patients listed
for THR and 316 listed for TKR were recruited into a single-centre double-blind randomised controlled trial. Participants were
randomly assigned (1:1) to receive local anaesthetic infiltration and standard care or standard care alone. Participants and outcomes
assessors were masked to group allocation. The primary outcome was pain severity on the WOMAC Pain Scale at 12 months after
surgery. Analyses were conducted using intention-to-treat and per-protocol approaches. In the hip trial, patients in the intervention
group had significantly less pain at 12 months postoperative than patients in the standard care group (differences in means: 4.74;
95% confidence interval [CI]: 0.95-8.54; P 5 0.015), although the difference was not clinically significant. Post hoc analysis found
that patients in the intervention groupweremore likely to have none tomoderate pain than severe pain at 12months than those in the
standard care group (odds ratio: 10.19; 95% CI: 2.10-49.55; P 5 0.004). In the knee trial, there was no strong evidence that the
intervention influenced pain severity at 12 months postoperative (difference in means: 3.83; 95% CI:20.83 to 8.49; P5 0.107). In
conclusion, routine use of infiltration could be beneficial in improving long-term pain relief for some patients after THR.
Keywords: Hip, Knee, Arthroplasty, Pain, Randomised controlled trial
1. Introduction
Primary total hip replacement (THR) and primary total knee
replacement (TKR) are 2 of themost commonly performed elective
surgical procedures, with 76,448 THR operations and 76,497 TKR
operations performed in England andWales in 2012.24 Projections
indicate increased demand in the coming decades.30 Joint
replacement is usually performed to relieve pain and improve
function related to osteoarthritis and is effective for the majority of
patients. However, in the postoperative period, up to half of the
patients report moderate or severe pain on the first post-
operative day.36 In the longer-term, between 7% and 23% of
patients with THR and between 10% and 34% of patients with
TKR report an unfavourable pain outcome at 3 months to
5 years after surgery.2
Given the prevalence and impact of chronic pain,13 it is
important to investigate interventions to reduce chronic post-
surgical pain after joint replacement. Evidence from several types
of surgery indicates that severe acute postoperative pain is a risk
factor for chronic postsurgical pain. This has been highlighted in
joint replacement, breast surgery, inguinal hernia repair, and
thoracic surgery.15 Mechanisms for the transition from acute to
chronic postsurgical pain are likely to be multifactorial. It is
probable that the large amount of noxious input induced by
surgery contributes to this transition through hyperexcitability and
sensitisation of neurones within the central nervous system,
which can lead to long-lasting amplification of pain signalling
within the spinal cord.15
In orthopaedic surgery, local anaesthetic infiltration has been
found to be effective at significantly reducing pain severity in the first
48 hours after surgery.19 However, because of a lack of trials with
longer-term follow-up, it is not known whether benefits of local
anaesthetic infiltration extend to reducing chronic postsurgical pain.
Studies on the trajectory of recovery after joint replacement illustrate
that althoughmuchof thepain relief fromsurgery occurs in the first 3
months, improvements in pain continue throughout the first year
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postoperative.5 The aim of these 2 double-blind randomized
controlled trials (RCTs) with allocation concealment was to
determine whether intraoperative local anaesthetic infiltration could
significantly reduce pain at 12 months after THR or TKR.
2. Methods
2.1. Design overview
Two single-centre double-blind RCTs (the Arthroplasty Pain
Experience [APEX] trials) were conducted: one with patients
undergoing THR and the other with patients undergoing TKR.
The design of the 2 trials was similar except for standard
anaesthetic care, and these differences are described in more
detail below. The protocol for these trials has been published
previously.34 The APEX trials were approved by Southampton
and South West Hampshire Research Ethics Committee
(09/H0504/94), and all participants provided informed written
consent. The trials were registered as an International Stand-
ardised Randomized Controlled Trial (96095682) and as a Clinical
Trial of an Investigational Medicinal Product with the Medicine
Healthcare and Regulatory Authority (18524/0215/001-0001)
and EudraCT (2009-013817-93). Both trials were overseen by
a Data Monitoring Committee and Trial Steering Committee, who
regularly reviewed safety data and monitored trial conduct.
2.2. Setting and participants
Eligible patients were listed for a primary unilateral THR or TKR for
osteoarthritis at a UK elective orthopaedic centre. Exclusion
criteria were (1) medical comorbidity that precluded spinal
anaesthesia, regional blocks, or strong analgesics postopera-
tively because inability to tolerate these pain relief strategies may
have influenced the trial results; (2) severe dementia or psychiatric
illness; (3) listing for simultaneous bilateral joint replacement; (4)
previous participation in the trial; (5) inability to understand
English. Patients were recruited at the preoperative assessment
clinic by a research nurse and randomized before surgery by the
trial administrator.
2.3. Randomization
Treatment allocation was conducted remotely through the Bristol
Randomised Trials Collaboration to maintain allocation conceal-
ment. Patients were allocated on a 1:1 ratio to receive the
intervention plus standard care or standard care alone using
minimisation. Baseline joint pain severity and surgical approach
were used as minimisation factors. The trial administrator
informed the operating surgeon and anaesthetist of treatment
allocation on the day of surgery. Participants and trial research
nurses were blinded to treatment allocation.
2.4. Standard care and intervention treatment: total
hip replacement
Standard anaesthetic care consisted of a spinal anaesthetic with 3
mL of 0.5%plain bupivacaine placed at the L3/4 or L4/5 interspace.
Intraoperatively, the patient was awake, sedated, or under light
general anaesthetic depending on patient and anaesthetic factors.
The intervention group received the same anaesthetic regime, plus
an intraoperative local anaesthetic infiltration that consisted of 60mL
of 0.25% bupivacaine with 1 in 200,000 adrenaline. The local
anaesthetic mixture was injected into the joint capsule and short
external rotators (5 mL), fascia (20 mL), fat (15 mL), and
subcutaneous tissue (20 mL) before closure of the wound.
2.5. Standard care and intervention treatment: total
knee replacement
In line with evidence-based guidance from PROSPECT (pro-
cedure specific postoperative pain management), standard
anaesthetic care consisted of a femoral nerve block and a spinal
or general anaesthetic, depending on patient factors.28 The
intervention group received the same anaesthetic regime, plus an
intraoperative local anaesthetic infiltration that consisted of 60mL
of 0.25% bupivacaine with 1 in 200,000 adrenaline. The local
anaesthetic mixture was injected directly into the posterior
capsule (25 mL), medial and lateral capsule (10 mL), fascia and
muscle (10 mL), and subcutaneous tissues (15 mL), before
wound closure. Full details of treatment in both arms are
described in the protocol.34
2.6. Outcomes and follow-up
Baseline data, including sociodemographics, were collected pre-
operatively before randomization, and outcomes were assessed
during the postoperative inpatient stay, and at 3, 6, and 12 months
postoperatively.
2.6.1. Primary outcome
The primary outcomewas the self-completionWesternOntario and
McMaster Universities Osteoarthritis Index (WOMAC) Pain Scale
score at 12monthspostoperative.1 The 5-itemWOMACPain Scale
is a widely used and validated measure of joint pain severity when
performing daily activities. Scores were transformed onto a 0-to-
100 scale, with lower scores indicating more severe pain.
2.6.2. Secondary outcomes
Secondary outcomes were collected during the postoperative
inpatient stay, and at 3, 6, and 12 months postoperative. Pain
severity on admission to and discharge from the recovery ward was
rated on a 4-point Likert-type scale (none to severe). Pain severity for
the remainder of the day of surgery was rated every 4 hours on
a 0-to-10 scale (best to worst). On postoperative days 1 to 3,
patients rated the severity of night pain, pain onmovement, and pain
at rest on a 100-mm visual analogue scale. Satisfaction with pain
relief and occurrence of nausea and vomiting was collected daily
during the in-patient stay. Length of hospital stay and postoperative
analgesia use were extracted frommedical records. At 3, 6, and 12
months postoperative, patients completed the WOMAC Function,
Pain, and Stiffness subscales1 and the Intermittent and Constant
Osteoarthritis Pain (ICOAP) questionnaire.12 The painDETECT
questionnaire,8 a measure of neuropathic pain, was completed at
12 months postoperative. Details of medical and surgical adverse
events were recorded throughout the trial through review of medical
records, patient self-report, and assessment by a research nurse.
2.6.3. Effect modifiers
Measures of possible effect modifiers included: sociodemo-
graphic factors, Functional Comorbidity Index,10 Kellgren and
Lawrence16 osteoarthritis grading scheme, Hospital Anxiety and
Depression Scale,37 Pain Self-Efficacy questionnaire,25 Illness
Perceptions Questionnaire-Revised,22 and Brief COPE.4
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2.7. Sample size
A sample size of 300 patients in each trial provided 90% power
to detect a difference of 0.5 SDs on the WOMAC Pain Scale at
12 months postoperative with a 2-sided 1% significance level,
allowing for a 20% dropout rate. Previous research suggests
SDs of approximately 17 on the WOMAC Pain Scale before
surgery.31 Hence, a difference between the trial arms of 0.5
SDs equates to a difference of approximately 8 to 9 units on the
WOMAC Pain Scale, which represents a minimal perceptible
clinical improvement.7
2.8. Statistical analysis
The hip and knee trials were analysed separately and all analyses
were undertaken in Stata 13.1.
2.8.1. Primary analyses
Following a predefined analysis plan agreedwith the Trial Steering
Committee,34 linear regressions were used to estimate between-
group difference in mean WOMAC Pain scores at 12 months
postoperative, adjusted for preoperative WOMAC Pain scores
and surgical approach. All patients in their originally assigned
groups with available primary outcome data (281 THR patients
and 273 TKR patients) were included in the primary analyses
(intention-to-treat complete cases, ITT-CC).
2.8.2. Sensitivity analyses
Analyses were repeated on all randomized 322 THR patients
and 316 TKR patients using multiple imputation technique by
chained equations under a missing at random framework (20
imputations for the THR trial, 25 imputations for the TKR trial)
stratified by randomization arm to handle missing outcomes32
(intention-to-treat imputed, ITT-imputed). The analyses were
also conducted on a per-protocol basis (266 THR patients and
259 TKR patients) (per-protocol-complete cases, PP). Also as
sensitivity analyses, any potential unbalance in patients’
baseline characteristics was controlled for in the ITT-CC, ITT-
imputed, and PP analyses.
2.8.3. Post hoc analyses
Patient-reported outcome measures such as the WOMAC Pain
score are bounded (0-100), limiting the ability of the question-
naire to detect improvement beyond the bounds of the scoring.
The resulting ceiling or floor effect can generate a nonnormally
distributed score, especially if a substantial proportion of the
sample is affected. This can impact the robustness of the
coefficient SE, confidence intervals, and P values obtained from
a linear regression (through violations of the assumptions of
homoscedasticity and normality). To explore the potential
impact of the ceiling effect on the intervention effect, 2 further
sensitivity analyses were conducted. First, transformations of
WOMAC Pain scores using appropriate functions to obtain
a continuous primary outcome that could be modelled with
a linear regression were investigated. Second, the scores were
modelled as an ordered categorical variable using published
threshold definitions (severe [0-50], moderate [51-75], mild
[76-99], no [100] pain).35 These categories relate to the original
ordinal WOMACPain scale, eg, a patient who reports no pain for
every item will score 100, a patient who reports mild pain on all
the items will score 75 and so forth. A partial proportional-odds
regression was used to model this new outcome.11,33 The
model automatically generates logical and systematic group-
ings of the outcome categories: category 1 vs 2 to 4; 1 to 2 vs 3
to 4; 1 to 3 vs 4. It then performs a series of binary logistic
regressions on those different grouping within a single analytical
framework. In our context, the model explored the probability of
having none, mild, or moderate vs severe pain; the probability of
having no or mild pain vsmoderate or severe pain; and finally the
probability of having no pain vs pain (mild, moderate, severe).
The model produced the odds ratio associated with the
intervention effect for each of the outcome category groupings
adjusted for the preoperative WOMAC Pain scores and surgical
approach.
2.8.4. Secondary analyses
A similar strategy was used to analyse the secondary outcomes
and is described in more detail in Web appendix 1 (available
online as Supplemental Digital Content at http://links.lww.com/
PAIN/A42).
3. Results
3.1. Participants
BetweenNovember 2009 and February 2012, 630 eligible patients
listed for THR and 585 patients listed for TKR were approached to
take part in the trial. For the THR trial, 322 (51%) patients were
recruited and randomized, 163 to the intervention arm and 159 to
the standard care arm (Fig. 1A). For the TKR trial, 316 (54%) were
recruited and randomized, 157 to the intervention arm and 159 to
the standard care arm (Fig. 1B). Primary outcome data were
collected from281 (87%) patientswith THRand273 (86%) patients
with TKR. Baseline demographic and clinical characteristics were
generally well balanced between the arms in both trials (Tables 1
and 2). In the THR trial, some differences between trial arms in
gender, living arrangement, and comorbidities were observed. In
the TKR trial, slight imbalances between arms in working status,
comorbidities, anxiety, and depression were observed.
3.2. Total hip replacement
3.2.1. Primary analysis
Themajority of patients in both trial arms had excellent pain relief
at 12months after surgery, with amedianWOMACPain score in
the intervention arm of 100 (interquartile range [IQR]: 10) and in
the standard care arm of 95 (IQR: 20; Web Appendix 2, available
online as Supplemental Digital Content at http://links.lww.com/
PAIN/A42). The primary analysis (ITT-CC) showed that patients
in the intervention group had a higher (better) mean pain score at
12 months postoperative compared with patients in the
standard care group (between-group difference in mean:
4.74; 95% confidence interval [CI]: 0.95-8.54; P 5 0.015;
Table 3 and Fig. 2).
3.2.2. Sensitivity analyses
The effect of the intervention was stronger in the ITT-imputed
analysis (difference in means: 5.35; 95% CI: 1.33-9.34;
P 5 0.009; Table 3 and Fig. 2) but weaker in the PP analysis
(P5 0.051; Table 3 and Fig. 2). The between-group difference
in mean WOMAC Pain scores remained after further
adjustments for baseline imbalances between groups (ITT-
CC: P 5 0.022; ITT-imputed: P 5 0.028; Fig. 2 and Web
June 2015·Volume 156·Number 6 www.painjournalonline.com 1163
  Copyright  2015 by the International Association for the Study of Pain. Unauthorized reproduction of this article is prohibited.
appendix 2, available online as Supplemental Digital Content at
http://links.lww.com/PAIN/A42), although the differences was
less apparent in the adjusted PP analyses (Fig. 2 Web
appendix 2, available online as Supplemental Digital Content
at http://links.lww.com/PAIN/A42).
3.2.3. Post hoc analysis of the primary outcome
An important ceiling effect was observed, with approximately 41%
of the THR trial participants reporting no pain at 12 months after
surgery. As a result, several key assumptions underlying the use of
linear regression (homoscedasticity and normality), the a priori
A
Figure 1. Recruitment, randomization, and follow-up of total hip replacement patients (A) and total knee replacement patients (B).
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primary analysis, were strongly violated and remained so with
different continuous transformations of the WOMAC Pain scores.
The modelling of the categorical version of the WOMAC Pain
scores with partial proportional-odds regressions confirmed an
effect of the intervention. Patients in the intervention group were
more likely to have no, mild, or moderate pain than severe pain at
12 months postoperative than those in the standard care group
(odds ratio: 10.19; 95% CI: 2.10-49.55; P 5 0.004; Table 4).
B
Figure 1. Continued
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However, the likelihood of having no or mild pain rather than
moderate or severe pain and the likelihood of having no pain
rather than any level of pain was not different between the 2
groups. Therefore, the intervention only affected the likelihood of
having severe pain. These findings remained after further
adjustments for imbalances between groups (Web appendix
2, available online as Supplemental Digital Content at http://
links.lww.com/PAIN/A42).
Table 1
Baseline characteristics of participants by trial arm for the total hip replacement and total knee replacement trial.
Hip Knee
Intervention (n 5 163) Standard care (n 5 159) Intervention (n 5 157) Standard care (n 5 159)
Age 66.0 (11.4) 66.4 (10.2) 69.5 (9.4) 68.7 (7.9)
Body mass index 28.9 (5.6) 29.4 (5.4) 32.4 (6.5) 32.8 (6.5)
Self-efficacy* 35.6 (13.7) 34.2 (13.3) 36.0 (13.4) 37.3 (12.0)
WOMAC Pain† 43.4 (19.0) 41.5 (17.9) 42.5 (17.3) 42.4 (16.1)
WOMAC Function† 43.7 (20.2) 41.2 (17.2) 46.1 (17.7) 46.0 (17.9)
WOMAC Stiffness† 47.4 (24.9) 42.6 (20.7) 41.9 (21.0) 41.1 (19.4)
Data shown as mean (SD).
* Pain Self-Efficacy questionnaire; scores range from 0 to 60 (worst to best).
† Scores range from 0 to 100 (worst to best).
Table 2
Baseline characteristics of participants by trial arm for the total hip replacement and total knee replacement trial.
Hip Knee
Intervention (n 5 163) Standard care (n 5 159) Intervention (n 5 157) Standard care (n 5 159)
Female sex 86 (53) 103 (65) 81 (52) 86 (54)
Living arrangement
Live with someone 110 (68) 123 (77) 112 (71) 103 (65)
Live alone 43 (26) 32 (20) 41 (26) 44 (28)
Missing 10 (6) 4 (3) 4 (3) 12 (7)
Working status
Paid employment or voluntary work 47 (29) 52 (33) 41 (26) 27 (17)
Retired 104 (64) 104 (65) 111 (71) 117 (74)
Missing 12 (7) 3 (2) 5 (3) 15 (9)
Education
Compulsory age or before 98 (60) 108 (68) 115 (73) 109 (69)
College 34 (21) 30 (19) 26 (17) 25 (16)
University 20 (12) 17 (11) 9 (6) 10 (6)
Missing 11 (7) 4 (2) 7 (4) 15 (9)
Comorbidities*
0 3 (2) 3 (2) 4 (3) 1 (1)
1-3 127 (78) 122 (77) 108 (69) 104 (66)
4 or more 21 (13) 28 (18) 38 (24) 43 (27)
Missing 12 (7) 6 (4) 7 (5) 11 (7)
Anxiety†
Definite 26 (16) 31 (19) 33 (21) 18 (11)
Potential 26 (16) 23 (15) 24 (15) 32 (20)
None 100 (61) 100 (63) 93 (59) 99 (62)
Missing 11 (7) 5 (3) 7 (5) 10 (6)
Depression†
Definite 20 (12) 25 (16) 30 (19) 16 (10)
Potential 25 (15) 28 (18) 29 (19) 30 (19)
None 106 (65) 101 (63) 91 (58) 104 (65)
Missing 12 (7) 5 (3) 7 (4) 9 (6)
Surgical approach
Posterior 151 (93) 147 (92)
Lateral 12 (7) 12 (8)
Medial parapatellar 122 (78) 125 (79)
Subvastus 35 (22) 34 (21)
Kellgren and Lawrence grade‡
,3 4 (3) 8 (4) 1 (1) 3 (2)
$3 136 (83) 128 (81) 133 (84) 133 (84)
Noninterpretable 12 (7) 12 (8) 1 (1) 5 (3)
Missing 11 (7) 11 (7) 22 (14) 17 (11)
Data shown as n (%).
* Functional Comorbidity Index.
† Hospital Anxiety and Depression Scale. Scores of 0 to 7 5 no anxiety or depression, 8 to 10 5 potential anxiety or depression, .10 5 definite anxiety or depression.
‡ Grades range from 0 to 4 (normal joint to severe osteoarthritis).
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3.2.4. Secondary outcomes
Therewas nostrong evidence of an effect of the intervention on any
of the secondary outcomes (Web appendix 3, available online as
Supplemental Digital Content at http://links.lww.com/PAIN/A42),
with the exception of neuropathic pain assessed by the
painDETECT questionnaire. At 12 months postoperative, patients
in the intervention arm reported significantly less neuropathic pain
than patients in the standard care arm (ITT-CC relative risk: 0.17;
95% CI: 0.04-0.76; P 5 0.021; Web Appendix 3, available online
as Supplemental Digital Content at http://links.lww.com/PAIN/
A42, Table 12a). These findingswere similar in the ITT-imputed and
PP analyses, and after further adjustments for baseline imbalances
between groups.
3.2.5. Safety data
Postsurgical superficial and deep wound infection rates
were similar in the intervention group and standard care group
(1.8% vs 1.9%; P5 1.000). There were no differences in rates of
serious adverse events between groups (Web appendix 4,
available online as Supplemental Digital Content at http://links.
lww.com/PAIN/A42).
3.3. Total knee replacement
3.3.1. Primary analyses
Themajority of patients in both trial arms had goodpain relief at 12
months after surgery, with a median WOMAC Pain score in the
intervention group of 90 (IQR: 30) and in the standard care group
of 85 (IQR: 35;Web appendix 2, available online as Supplemental
Digital Content at http://links.lww.com/PAIN/A42). The primary
analysis revealed that therewasno strongevidence of a difference
in mean pain severity at 12 months after surgery between the
intervention and standard care groups (ITT-CC between-group
mean difference: 3.83; 95% CI: 20.83 to 8.49; P 5 0.107;
Table 3 and Fig. 2).
Table 3
Primary analysis of WOMAC Pain scores at 12 months after total hip replacement and total knee replacement.
Hip Knee
Coefficient 95% CI P Coefficient 95% CI P
ITT-CC*† 4.74 0.95 to 8.54 0.015 3.83 20.83 to 8.49 0.107
ITT-imputed‡§ 5.35 1.33 to 9.34 0.009 3.33 21.21 to 7.88 0.150
PP‖{ 3.81 20.02 to 7.63 0.051 4.21 20.66 to 9.09 0.090
Linear regression adjusted for preoperative pain score and surgical approach.
* n 5 281.
† n 5 273.
‡ n 5 322.
§ n 5 316.
‖ n 5 266.
{ n 5 259.
CI, confidence interval; ITT-CC, intention-to-treat complete cases analysis; ITT-imputed, intention-to-treat with imputed information analysis; PP, per-protocol analysis.
Figure 2. Mean difference and 95% confidence interval in WOMAC Pain score on a 0-to-100 scale for the effect of local anaesthetic wound infiltration in those
randomized to treatment vs standard care. Three analytic models were used: (1) intention to treat with complete case (ITT-CC), (2) intention to treat with missing
follow-up data imputed (ITT-imputed), and (3) a per-protocol approach (PP). The primary analysis (Primary) (solid lines) was adjusted for preoperative pain score
and surgical approach, and further analyses (Adjusted) (dashed lines) were additionally adjusted for minor imbalances in baseline characteristics. P values are
presented for analyses reaching nominal significance P , 0.05.
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3.3.2. Sensitivity analyses
This absence of an intervention effect was consistently observed
throughout the different approaches (Table 3 and Fig. 2) and in the
adjusted analysis (Fig. 2 and Web appendix 2, available online as
Supplemental Digital Content at http://links.lww.com/PAIN/A42).
3.3.3. Post hoc analysis of the primary outcome
Similar to the THR trial, 26% of patients in the TKR trial reported no
pain at 12 months after surgery. The assumptions of the linear
regression were violated and no suitable continuous transforma-
tion of the primary outcome was found. The partial proportional-
odds model also revealed no difference in pain severity between
the 2 groups with the exception of the PP analysis, in which there
was some evidence that the odds of having no or mild pain rather
than moderate or severe pain was higher for those in the
intervention group than the standard care group (Table 4).
Therefore, there was some weak evidence that patients who
actually received the intervention were more likely to report no or
mild pain than a higher level of pain. Similar results were found in
the adjusted analysis (Web appendix 2, available online as
Supplemental Digital Content at http://links.lww.com/PAIN/A42).
3.3.4. Secondary outcomes
There was no strong evidence of an effect of the interven-
tion on any of the secondary outcomes (Web appendix 3,
available online as Supplemental Digital Content at http://links.
lww.com/PAIN/A42).
3.3.5. Safety data
Postsurgical superficial and deep wound infection rates were
similar in the intervention group and standard care group (3.2%
vs 1.9%; P 5 0.500). There were no differences in rates of
serious adverse events between groups (Web appendix 4,
available online as Supplemental Digital Content at http://links.
lww.com/PAIN/A42).
4. Discussion
This article reports the findings of the first large double-blind RCTs
with allocation concealment designed to investigate the effec-
tiveness of local anaesthetic infiltration at reducing chronic pain at
12 months after THR and TKR. These trials found some evidence
that local anaesthetic wound infiltration can reduce pain severity
at 12 months after THR, although the evidence was less clear for
TKR. In the a priori analysis of the primary outcome, we found a 4
to 5 point difference in the mean WOMAC Pain score between
patients in the intervention and standard care group of the THR
trial and a 3- to 4-point difference in the TKR trial. The minimally
clinically important difference on the 100-point WOMAC Pain
scale is 8 to 9 points.7 Therefore, it could be argued that there is
little evidence to support the use of infiltration for long-term pain
relief, because although the results were statistically significant in
the THR trial, the benefit will not be clinically meaningful.
However, it is important to interpret these results in the context
of outcomes after joint replacement. The majority of patients
report little or no pain after joint replacement.2 Therefore, this
intervention can only improve the outcome of the patients who
would otherwise experience an unfavourable long-term pain
outcome, which the literature suggests is approximately 10% of
patients with THR and 20% of patients with TKR.2 Our post hoc
analysis of the WOMAC Pain score highlighted the potential of
local wound infiltration to reduce the number of patients with
severe pain after THR.
The findings from these trials suggest that local anaesthetic
infiltration could be beneficial in reducing long-term pain severity
after THR for some patients. We also found evidence that the
intervention reduces neuropathic pain at 12 months after THR,
indicating that infiltration could benefit those patients who may
otherwise experience the most severe long-term and/or
neuropathic pain after THR, both of which can be difficult to
treat once established.26 We found no difference in adverse
events between trial arms. Our trials are phase IV pragmatic
studies of effectiveness, and we were not powered for the
analysis of adverse events; however, previous evidence in local
anaesthetic infiltration indicates no concerns in safety pro-
file.3,6,17,18,20,21,23,27 Administering local anaesthetic infiltration
in THR is not an expensive procedure, has no safety concerns,
and has the potential to benefit a minority of patients with the
poorest long-term pain outcomes.
The lack of an effect of the intervention on chronic pain after
TKR could be due to the use of femoral nerve blockwithin the trial.
Femoral nerve block is a well-established method of providing
analgesia after TKR and in our centre is included in themultimodal
anaesthesia regimen provided as part of standard care.
Consistent with our findings, 2 small RCTs with short-term
follow-up showed limited additional pain relief for local anaes-
thetic infiltration when used in conjunction with a femoral nerve
block.17,18 Although they are effective in the management of
Table 4
Post hoc analysis of WOMAC Pain scores at 12 months after
total hip replacement and total knee replacement.
Odds ratio 95% CI P
HIP
[Moderate-mild-none] vs ref5[severe]
ITT-CC* 10.19 2.10-49.55 0.004
ITT-imputed† 6.81 1.81-25.68 0.005
PP‡ 8.93 1.83-43.62 0.007
[Mild-none] vs ref5[severe-moderate]
ITT-CC* 1.72 0.90-3.30 0.100
ITT-imputed† 1.76 0.95-3.26 0.073
PP‡ 1.56 0.81-3.02 0.186
[None] vs ref5[severe-moderate-mild]
ITT-CC* 1.40 0.89-2.25 0.168
ITT-imputed† 1.42 0.90-2.26 0.136
PP‡ 1.31 0.80-2.14 0.277
Knee
[Moderate-mild-none] vs ref5[severe]
ITT-CC§ 1.28 0.60-2.72 0.515
ITT-imputed‖ 1.28 0.63-2.61 0.497
PP{ 1.28 0.60-2.72 0.515
[Mild-none] vs ref5[severe-moderate]
ITT-CC§ 1.61 0.96-2.71 0.071
ITT-imputed‖ 1.48 0.89-2.48 0.131
PP{ 1.75 1.03-2.97 0.039
[None] vs ref5[severe-moderate-mild]
ITT-CC§ 1.41 0.82-2.43 0.216
ITT-imputed‖ 1.39 0.82-2.35 0.227
PP{ 1.48 0.85-2.59 0.168
Partial proportional-odds model adjusted for preoperative pain score and surgical approach.
* n 5 281.
† n 5 322.
‡ n 5 266.
§ n 5 273.
‖ n 5 316.
{ n 5 259.
ITT-CC, intention-to-treat complete cases analysis; ITT-imputed, intention-to-treat with imputed information
analysis; PP, per-protocol analysis.
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acute postsurgical pain, femoral nerve blocks are associated with
a temporary decrease in quadriceps function that may limit early
mobilization, and an increased risk of falls.29 Future research
should evaluate the long-term effectiveness of local anaesthetic
infiltration vs femoral nerve blocks after TKR surgery.
Strengths of these trials include the long-term postoperative
follow-up, use of robust and validated outcome measures, good
rates of data collection for the primary outcomemeasure, and use
of an independent allocation system and blinding to minimise
bias. The sample is representative of the population undergoing
THR and TKR, with a similar disease profile, gender mix and age
range as reported by the National Joint Registry of England and
Wales24 and other national registries,9 and thus we believe the
results to be generalisable. However, it is also important to
acknowledge the limitations of these trials when interpreting the
results. A large number of patients in both trials reported no pain
on the WOMAC Pain Scale at 12 months postoperative; the
resulting skewness of the data violated the assumptions of our
a priori linear regression, and therefore we conducted post hoc
analysis of the primary outcome using a categorical version of the
WOMACPain scores. In this analysis, the number of patients with
severe chronic pain was small, and the wide 95% confidence
intervals for the odds ratios highlight that the results should be
interpreted with caution. It is also important to acknowledge that
the trials were not powered for the analyses of the primary
outcome as categorical variables or to detect differences in the
treatment effect for the secondary outcomes.
For many patients, THR and TKR is an effective treatment for
painful osteoarthritis, and additional interventions to improve
pain relief are not required. However, a sizeable proportion of
people report chronic postsurgical pain.2 Preoperative identifi-
cation of patients at high risk of a poor outcome has proved
challenging,14 and until better predictive models can be
developed, it is unfeasible to target interventions at high-risk
patients. Easily implementable and cost-effective interventions
that can be administered to all patients undergoing joint
replacement are needed to reduce the number of patients with
chronic pain after surgery. Findings of our trials suggest that
local anaesthetic infiltration is beneficial for decreasing long-
term pain in patients with THR, although further research is
required to determine whether the intervention is also beneficial
for patients undergoing TKR. Given that approximately 80,000
THR operations are performed annually in England and Wales24
and 7% to 23% of patients are likely to develop severe chronic
postsurgical pain,2 our findings suggest that routine use of local
anaesthetic infiltration has the potential to improve pain
outcomes for between 4600 and 15,300 patients every year.
A full economic evaluation of the cost-effectiveness of this
intervention within the APEX trials will be reported in a future
publication.
In conclusion, these trials provide evidence that local
anaesthetic infiltration reduces chronic pain at 1 year after THR,
suggesting that the routine use of infiltration could improve long-
term pain relief.
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